Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 10/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201807 | 0.88 | POLB (0.42) | SSTR4SSTR1GRM2GPR119 | |
| SCHEMBL4603500 | 0.88 | POLB (0.42) | SSTR4SSTR1GRM2GPR119 | |
| SCHEMBL16105108 | 0.84 | GRM2 (0.46) | ITGA4GRM2ITGB1 | |
| SCHEMBL1396960 | 0.83 | SSTR4 (0.40) | ITGA4SSTR4SSTR1GRM2 | |
| SCHEMBL2200981 | 0.82 | ABCB1 (0.39) | SSTR4SSTR1GRM2GPR119 | |
| SCHEMBL2202034 | 0.82 | GPR119 (0.39) | SSTR4SSTR1GRM2GPR119 | |
| SCHEMBL4602385 | 0.82 | GPR119 (0.39) | SSTR4SSTR1GRM2GPR119 | |
| SCHEMBL29007980 | 0.80 | DPP4 (0.48) | SSTR4SSTR1 | |
| SCHEMBL30743362 | 0.78 | GPR119 (0.38) | GPR119 | |
| SCHEMBL16491270 | 0.78 | ITGA4 (0.42) | ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288351-B1 | NOVEL PYRROLIDONE DERIVATIVES FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | METAP2, METAP1, ENPEP | ITGA4 4360/4885SSTR4 1064/4885SSTR1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.